the modified Rankin Scale (mRS), commonly used stroke outcome scales, quantify activities of daily living or the extent of functional disabilities, respectively. However, they each fail to assess the broad multidimensional factors contributing to QoL. Ali et al 20 demonstrated correlation between mRS, BI, and QoL (generic and disease specific); self-reported QoL had a significantly stronger association with mRS while proxy QoL had stronger association with BI. 21, 22 The simple visual analogue scale (VAS), an easily used instrument to measure self-reported QoL, has been validated with excellent reliability in assessing global QoL, when compared with multi-item questionnaire tool, 23 and serves as an appropriate tool to measure QoL in the setting of stroke. [24] [25] [26] To date, there has been no large-scale prospective studies analyzing the relationship between QoL and stroke. 27 We report relationship of baseline VAS QoL in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) with subsequent stroke risk and changes in QoL after stroke.
Methods
All clinical sites had local ethics board approvals. Written informed consent was obtained from all subjects or their legally authorized representatives.
ALLHAT Design
Rationale and design of ALLHAT, sponsored by the National Heart, Lung, and Blood Institute, have been previously published. 28 ALLHAT was a randomized, double-blinded trial in 42 418 high-risk hypertensive patients. ALLHAT's main eligibility criteria were (1) age ≥55 years, (2) hypertension, and (3) ≥1 additional risk factors for heart attack. Mean duration of treatment and follow-up was 4.9 years. Patients were assigned to 4 treatment groups: amlodipine, lisinopril, chlorthalidone, and doxazosin. Doxazosin arm was terminated early because of a significantly higher rate of cardiovascular disease and was not included in this analysis.
Outcomes
Primary end point of ALLHAT was the composite of fatal coronary heart disease and nonfatal MI. Four major protocol-defined prehypothesized secondary outcomes were (1) all-cause mortality, (2) combined coronary heart disease, (3) strokes, and (4) combined cardiovascular disease. QoL was a prespecified secondary outcome.
28

Quality of Life
Of ALLHAT participants, 28 534 (86%) completed at least 1 biannual VAS estimate of QoL. The VAS scale ranged from 0 to 100. This value was transformed using the statistical Torrance transformation. 29, 30 We analyzed mean baseline QoL and transformed QoL (TQoL) before and after stroke for each participant.
Statistical Analysis
Baseline characteristics are described by stroke status: participants with no stroke versus fatal or nonfatal stroke. Characteristics are also described for participants with no stroke versus those with nonfatal stroke. Groups are compared by t tests for continuous variables and χ 2 tests for categorical variables. Mean baseline QoL and TQoL were analyzed by stroke status and by treatment groups. T tests were used to compare between QoL and TQoL by stroke status. Cox regressions were used to evaluate the impact of baseline QoL and TQoL on stroke status, looking at the QoL variables both continuously and by quartile, both unadjusted and adjusted for selected baseline variables (antihypertensive treatment group, age, sex, race, history MI or stroke, diabetes mellitus, history 28 **In-trial deaths separate from/does not include incident stroke deaths. QoL indicates quality of life.
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of coronary heart disease, smoking status, and baseline systolic blood pressure, diastolic blood pressure, atrial fibrillation, total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides, and aspirin use). Five-year cumulative stroke rates were estimated using the Kaplan-Meier method. For participants with nonfatal stroke, QoL and TQoL were compared prestroke and poststroke. Two analyses were performed: (1) using baseline QoL or TQoL and the first poststroke QoL or TQoL, and (2) using average of all prestroke QoL or TQoL measurements and the average of all poststroke QoL or TQoL measurements. The difference between prestroke and poststroke values was calculated, and t tests were used to evaluate if changes differed from 0. Analyses were stratified by treatment group, age, race, and sex. Last, predictors of prestroke to poststroke changes in QoL and TQoL were evaluated using linear regression, both univariate and multivariate, by age subgroups and for the total group. These were also done in the manners described above, using both single and average prestroke and poststroke values. Results using QoL and TQoL were similar; therefore, only results for TQoL are presented. Similarly, prestroke versus poststroke change results were similar using single and average values; therefore, only results using single prestroke and poststroke VAS are presented.
All analyses were done in STATA by the ALLHAT Coordinating Center.
Results
The consort diagram ( Figure 1 ) outlines participants in ALLHAT randomized to each treatment arm (chlorthalidone, amlodipine, and lisinopril) and numbers of subjects no stroke versus with fatal and nonfatal in-trial strokes. Over mean 4.9 years of follow-up, 683 (4.5%), 382 (4.2%), 460 (5.1%) of 33 357 patients randomized to chlorthalidone (n=15 255), amlodipine (n=9048), and lisinopril (n=9054) groups experienced strokes, respectively. Mean times to stroke were similar across treatment arms at 2.67±1.75 years for chlorthalidone, 2.66±1.73 years for amlodipine, and 2.54±1.73 years for lisinopril arms. Stroke-related mortality across randomized groups were also similar between groups: chlorthalidone (n=146; 21%), amlodipine (n=82; ALLHAT indicates Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; QoL, quality of life; and SBP, systolic blood pressure.
*For trial eligibility, participants had to have at least 1 other risk factor in addition to hypertension. †History of myocardial infarction or stroke; history of coronary revascularization; major ST-segment depression on T wave inversion on any ECG in the past 2 years; other ASCVD (please consult original ALLHAT trial design for detailed inclusions).
‡Transformed quality of life-The Torrance transformation was used so that the distribution of QoL utilities better matched the standard utility values, such as the time tradeoff or standard gamble. 31, 32 Table 1 shows baseline characteristics of subjects with stroke compared with those without. There are significant differences between groups, reflecting established risk factors, such as age, race (blacks>non-black), sex (man>woman), educational attainment, aspirin use (higher in the stroke group), higher systolic blood pressure, atherosclerotic cardiovascular disease, history of stroke or MI, baseline atrial fibrillation, type 2 diabetes mellitus, high-density lipoprotein (all P<0.001).
Mean baseline TQoLs (Table I in Table 2 and Figure 2 show the association between baseline TQoL and fatal/nonfatal stroke outcomes. Cox proportional hazards regression analyses were done with and without adjustments for treatment group, age, sex, race, history of MI or stroke, diabetes mellitus, history of coronary heart disease, smoking, and baseline blood pressure values, atrial fibrillation, cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides, and aspirin use. In unadjusted model, hazard ratio (HR) of baseline TQoL per 0.1 U increase was significantly associated with in-trial strokes with HR 0.90 (95% confidence interval [CI], 0.87-0.93). After adjustment, HR for stroke events for baseline TQoL per 0.1 U increase was 0.93 (95% CI, 0.89-0.98). Figure 2 shows Kaplan-Meier event curves for first stroke up to 6 years after randomization by baseline TQoL quartiles. The lowest quartile demonstrated a 36% higher stroke risk (HR=1.36; 95% CI, 1.18-1.58). In adjusted model, lowest quartile showed an HR of 1.20 (95% CI, 1.00-1.44), equivalent to 20% higher stroke risk compared with highest quartile TQoL. The second lowest quartile had significantly higher stroke risk in unadjusted models (HR=1.16; 95% CI, 1.00-1.35) but not after risk factor adjustment (HR=1.02; 95% CI, 0.85-1.24). Table 3 and Figure 3 show prestroke and poststroke TQoL in patients with nonfatal strokes, stratified by treatment arm, age, sex, and race were compared. A total of 559 (47.1%) subjects with nonfatal stroke had prestroke and poststroke QoL scores (chlorthalidone n=250; amlodipine n=149; lisinopril n=160). Poststroke TQoLs were significantly lower than prestroke TQoLs cumulatively (−0.06; SD, 0.19; P<0.0001) and when stratified according to treatment groups (−0.04; SD, 0.19 in chlorthalidone; −0.08; SD, 0.19 in amlodipine; and −0.07; SD, 0.21 in lisinopril; P=0.12 for comparison across treatment groups). Mean changes in TQoL increased with age, −0.04 (P=0.08) in subjects 55 to 64 years, −0.06 (P≤0.0001) in 65 to 75 years, and −0.01 (P≤0.0001) in 75+ years although these differences are not significantly different across age groups Stroke rates by quartile of baseline transformed quality of life (TQoL). Kaplan-Meier event curves for first stroke up to 6 years after randomization, by baseline TQoL quartiles. In the adjusted model, the lowest quartile showed a hazard ratio of 1.20 (95% confidence interval, 1.00-1.44), equivalent to 20% higher stroke risk compared with highest quartile TQoL.
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November 2017 (P=0.18). There were no consistent patterns when TQoL was stratified by sex and race. The goal of our multivariate analyses (Table 3; Table II in the online-only Data Supplement) was to determine predictors of change in TQoL in participants with nonfatal stroke, unadjusted (Table 3) , and after adjusting for clinical risk variables (Table II in the online-only Data Supplement). Table 3 presents unadjusted TQoL change by treatment group, age, sex, and race. Most of the changes were significantly different from 0. However, there were no significant differences across treatment groups, age at stroke, sex, or race. Multivariable analyses, including tests for interaction for age at stroke and baseline TQoL and treatment group and baseline TQoL, are shown in Table II in the online-only Data Supplement. Baseline TQoL was a significant predictor of poststroke TQoL change. No other clinical risk factor significantly impacted TQoL change. Similarly, multivariate regression analysis stratified by age revealed that baseline TQoL was strongest predictor of poststroke change in TQoL in all age groups.
Discussion
The objective of this study was to determine effect of baseline QoL on stroke risk and outcomes in the ALLHAT study, demonstrating use of simple VAS after previous work has demonstrated VAS and its transformation useful in cost-effectiveness studies in ALLHAT study population. 31 The major findings of this study indicate that baseline QoL is significantly lower in those who experienced stroke during the average 4.9 years of ALLHAT follow-up, except in lisinopril treatment group. Subjects in lowest quartile of baseline TQoL had a 20% higher stroke risk compared with reference group of highest quartile in a model adjusted for commonly known stroke risk factors.
Change in QoL showed a strong age effect from 50 to 64, 65 to 74, and 75+ years, which trended across all treatment arms. Amlodipine group had greatest change in QoL and TQoL, but biological and functional meaning of this is unclear. There was no consistent effect by sex or ethnicity.
We examined risk factors for change in TQoL in both univariate and multivariate models. Baseline TQoL was the strongest predictor of average poststroke TQoL. A smaller effect was seen in stroke subjects <75 years of age. Greater TQoL change in older subjects is consistent with previous findings that stroke in older individuals is associated with less favorable outcomes. 32, 33 The study has several substantial limitations which affect the conclusions and generalizability. ALLHAT remains the largest antihypertensive treatment trial but was not designed as a stroke study. ALLHAT study was a parallel group study. We have created new subcohorts in our analysis of this secondary outcome measure, whose power to detect differences may be limited, although sample sizes remain large because of size of the complete ALLHAT study population. Conducted between 1994 and 2002, with an average of 4.9 years of follow-up (3.2 years for the Doxazosin group), this study unfortunately did not collect data on type of stroke (or prior stroke type), traditional neurological outcomes, nor currently used functional outcome measures (BI and mRS). No cognitive outcomes are available, limiting attribution of cognitive change because of stroke poststroke QoL. Furthermore, no clinical correlation 
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with QoL and activities of daily living is available and warrants future investigation. Special effort was made to recruit minorities, and 32% of final cohort were black non-Hispanic. 34 This group alone recorded 620 strokes (40% of total in-study strokes), which is a significant contribution to existing literature. Although this minority recruitment effort contributed to groundbreaking use of the primary outcome in changing hypertension treatment, ALLHAT is not a community-based study, and data on Hispanics and Native Americans are not available to make additional generalizations on the overall population. Furthermore, individuals may enroll in clinical drug studies for many reasons, further skewing the population studied from the general population.
Prior stroke was not an exclusion criteria for subjects, and inclusion of this group can skew data on baseline QoL measures which correlate with outcome QoL. For this reason, our analysis included analysis of QoL change with in-study stroke, and there is no evidence that subjects with prior strokes were preferentially represented in any treatment arm nor other subgroup. Aspirin usage was higher in subjects with stroke (which includes infarcts and cerebral hemorrhages), and this may affect clinical outcomes, 35, 36 and further analysis of the meaning of this effect cannot be considered. BI and mRS were not collected, and comparison with other stroke clinical trials is limited. 18, 37 The effect of lipid lowering was not included in our analyses and is beyond the scope of this article. Furthermore, generalization of our results to agents other than the treatment groups cannot be assessed.
In a study of ALLHAT size and breadth, it is inevitable that missing data will affect the analysis. There is no evidence of biased data ascertainment, and we acknowledge that missing follow-up data on QoL/TQoL poststroke might affect analytic conclusions although robustness and face validity of findings remain. Last, conclusions derived from subgroup analysis ( Table 2 ; Figure 3 ), especially when stratified by treatment groups, may be underpowered.
QoL is a multiply determined integrative function, 16, 38 and seeming simplicity of VAS captures a global measure but does not distinguish which QoL component contributes to the results. The magnitude of stroke risk change between highest to lowest QoL group suggests possibility lifestyle change affecting global QoL could make a contribution to stroke risk reduction.
The VAS is a simply administered validated instrument. Its application in this study has revealed important outcomes seen in other conditions, such as coronary artery bypass grafting, MI, hemodialysis, and diabetes mellitus. The use of a VAS tool for QoL assessment should be considered for inclusion in other stroke registries and clinical trials.
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